| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2017/032 | ||
|---|---|---|---|
| Date of filing | 20/07/2017 | ||
| Notification of Application Published | 23/08/2017 | ||
| Status | Granted | ||
| Notification of Grant Published | 03/10/2018 | ||
| Date of Expiry of SPC | 14/02/2032 | ||
| Applicant |
INCYTE HOLDINGS CORPORATION 1801 Augustine Cut-Off Wilmington DE 19803 UNITED STATES OF AMERICA |
||
| Patent Number | 2288610 | ||
| Title of Invention | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | ||
| Date of Expiry of Patent | 09/03/2029 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Baracitinib and pharmaceutically acceptable salts thereof. | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/16/1170 | ||
| Authorisation Date | 13/02/2017 | ||
| Identity of Product Authorised | Olumiant - baricitinib | ||
| Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||
| Renewal Fees | |||
| 04/09/2018 | Supplementary Protection Certificate Number 2017/032, having an expiry date of 14/02/2032 granted on 04/09/2018. | ||
| 01/12/2025 | CORRECTION: Product identity changed from "Baracitinib and pharmaceutically acceptable salts thereof" to "Baricitinib and pharmaceutically acceptable salts thereof". | ||